Scarica l'app Stockscreener
10.23
0.63%
-0.065
Dopo l'orario di chiusura:
10.24
0.005
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVAX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.30
Aprire:
$10.42
Volume 24 ore:
2.86M
Relative Volume:
0.59
Capitalizzazione di mercato:
$1.67B
Reddito:
$1.12B
Utile/perdita netta:
$440.30M
Rapporto P/E:
4.2995
EPS:
2.3805
Flusso di cassa netto:
$-251.02M
1 W Prestazione:
+2.56%
1M Prestazione:
+17.64%
6M Prestazione:
+28.26%
1 anno Prestazione:
+25.28%
Intervallo 1D:
$10.12
$10.61
Intervallo di 1 settimana:
$9.79
$11.05
Portata 52W:
$5.01
$11.97
Novavax Inc Stock (NVAX) Company Profile
Nome
Novavax Inc
Settore
Industria
Telefono
240-268-2000
Indirizzo
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
10.23 | 1.67B | 1.12B | 440.30M | -251.02M | 2.3805 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Iniziato | Citigroup | Sell |
| 2025-02-28 | Iniziato | BTIG Research | Buy |
| 2024-07-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Reiterato | B. Riley Securities | Buy |
| 2022-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-02 | Iniziato | Jefferies | Hold |
| 2022-09-22 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2022-02-22 | Ripresa | Jefferies | Buy |
| 2022-01-21 | Iniziato | Cowen | Outperform |
| 2021-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Reiterato | B. Riley FBR | Buy |
| 2020-06-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Reiterato | B. Riley FBR | Buy |
| 2020-05-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-08-14 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-28 | Downgrade | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-11 | Iniziato | Oppenheimer | Outperform |
| 2018-11-26 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Aggiornamento | Seaport Global Securities | Neutral → Buy |
Mostra tutto
Novavax Inc Borsa (NVAX) Ultime notizie
Nuvaxovid (Novavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - Yahoo Finance
How (NVAX) Movements Inform Risk Allocation Models - Stock Traders Daily
Jefferies Maintains Buy on Novavax, Inc. (NVAX) March 2026 - Meyka
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform - Investing.com
Assessing Novavax (NVAX) Valuation After Strong 2025 Results And Return To Profitability - simplywall.st
Novavax (NASDAQ:NVAX) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Novavax Q4 earnings preview: Wall Street expects wider losses amid diversification efforts - MSN
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement - MSN
Novavax stock hits over 1-year high: Is Sanofi’s flu-COVID shot the post-pandemic growth driver? - MSN
The 7 Most Hated Stocks on Wall Street Today | Investing - Money/ US News
NVAX: Pivot to platform partnerships and innovation drives growth, with profitability targeted by 2028 - TradingView
Novavax (NVAX) EVP granted 139,500 non-statutory stock options - Stock Titan
Novavax Inc. (NVAX) legal chief updates 152,000-share stock option terms - Stock Titan
Novavax (NVAX) EVP granted 177,500 options with revised terms - Stock Titan
Therapeutics Companies Exceed Q4 2025 Revenue Estimates, Led by Novavax and AmgenNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
NOVAVAX INC (NASDAQ:NVAX) Screens as a Minervini-Style High-Growth Momentum Candidate - ChartMill
How Investors Are Reacting To Novavax (NVAX) Swinging From Losses To Profits On Vaccine Revenue - simplywall.st
Update Recap: Can Novavax Inc. stock maintain growth trajectory2025 Stock Rankings & High Conviction Trade Alerts - Naître et grandir
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Assessing Novavax (NVAX) Valuation After Strong Earnings Beat And Return To Profitability - simplywall.st
Novavax (NVAX) CFO reports RSU vesting and 20,850 shares withheld for taxes - Stock Titan
Novavax (NVAX) EVP Elaine O'Hara nets shares from RSU vesting and tax withholding - Stock Titan
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax, Inc. $NVAX Stock Position Lowered by Vanguard Group Inc. - MarketBeat
Novavax at TD Cowen Conference: Strategic Shift to Adjuvant Licensing - Investing.com
Novavax (NVAX) EVP Elaine O'Hara receives major RSU and option grants - Stock Titan
[Form 4] NOVAVAX INC Insider Trading Activity - Stock Titan
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
NVAX: Pivoting to a partnership-driven model, the company targets profitability by 2028 with robust pipeline and deals - TradingView
Is Novavax, Inc. (NVAX) a Good Buy at the Moment? - Bitget
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
NVAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Trading Systems Reacting to (NVAX) Volatility - Stock Traders Daily
Sanofi Takes Charge of Novavax COVID Vaccine, Mixed Financial Projections Ahead - StocksToTrade
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVAX) 2026-02-28 - Seeking Alpha
Novavax Stock Faces Uncertain Future Amid Low Revenue Guidance - StocksToTrade
Assessing Novavax (NVAX) Valuation After Surprise Q4 Profitability And New Pfizer Licensing Deal - Yahoo Finance
How The Novavax (NVAX) Story Is Shifting Toward Licensing Income And COVID Recalibration - Yahoo Finance
Novavax (NASDAQ:NVAX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax (NASDAQ:NVAX) Trading Down 9.8%Here's What Happened - MarketBeat
Why Novavax (NVAX) Shares Are Falling Today - Finviz
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof (NASDAQ:NVAX) - Seeking Alpha
Novavax (NASDAQ:NVAX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Q4 2025 Earnings Call Transcript - Insider Monkey
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Nasdaq
H.C. Wainwright raises Novavax stock price target on guidance beat - Investing.com
NVAX: HC Wainwright & Co. Raises Price Target Amidst Buy Rating - GuruFocus
Novavax Inc Azioni (NVAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):